Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin

被引：0
|
作者：
Elisabeth E. Fransen van de Putte
Laura S. Mertens
Richard P. Meijer
Michiel S. van der Heijden
Axel Bex
Henk G. van der Poel
J. Martijn Kerst
Andries M. Bergman
Simon Horenblas
Bas W. G. van Rhijn
机构：
[1] The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital,Department of Urology
[2] University Medical Center Utrecht,Department of Urology
[3] The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital,Department of Medical Oncology
来源：
World Journal of Urology | 2016年 / 34卷
关键词：
Bladder cancer; Neoadjuvant chemotherapy; Dose dense; MVAC; Cisplatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：157 / 162
页数：5
相关论文
共 50 条
  • [41] TOLERANCE AND OUTCOMES OF NEOADJUVANT DOSE-DENSE METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN FOR MUSCLE-INVASIVE BLADDER CANCER AT AN AUSTRALIAN TERTIARY REFERRAL CENTRE
    Mak, Blossom
    Sved, Paul
    Vasilaras, Arthur
    Grimison, Peter
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 45 - 45
  • [42] Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis
    Chung, Doo Yong
    Kang, Dong Hyuk
    Kim, Jong Won
    Ha, Jee Soo
    Kim, Do Kyung
    Cho, Kang Su
    CANCERS, 2021, 13 (11)
  • [43] Early outcomes with neoadjuvant high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (HD-MVAC) or gemcitabine and cisplatin (GC) in muscle-invasive urothelial carcinoma of the bladder: A single-institution experience.
    Mitra, N.
    Monk, J. P.
    Pohar, K. S.
    Shabsigh, A.
    Sharp, D. S.
    Abaza, R.
    Box, G. N.
    Zynger, D. L.
    Vandlik, S. L.
    Bhinder, A. S.
    Olencki, T.
    Bahnson, R. R.
    Clinton, S. K.
    Mortazavi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses
    Culine, Stephane
    Gravis, Gwenaelle
    Flechon, Aude
    Soulie, Michel
    Guy, Laurent
    Laguerre, Brigitte
    Mottet, Nicolas
    Joly, Florence
    Allory, Yves
    Harter, Valentin
    Pfister, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [45] NEMIO: A randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) plus durvalumab plus /- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
    Thibault, C.
    Elaidi, R. T.
    Pouessel, D.
    Flechon, A.
    Borchiellini, D.
    Barthelemy, P.
    Huillard, O.
    Rouabah, M.
    Braychenko, E.
    Helali, I.
    Audenet, F.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S723 - S723
  • [46] Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan
    Mitsui, Yozo
    Okawa, Mizuho
    Hori, Shunsuke
    Uetani, Masato
    Kasahara, Mizuki
    Yamabe, Fumito
    Kobayashi, Hideyuki
    Nagao, Koichi
    Nakajima, Koichi
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (09) : 1030 - 1037
  • [47] A community hospital experience in the use of pen-operative dose-dense MVAC in patients with muscle-invasive bladder cancer (MIBC) treated with either robotic cystectomy (RC) or open cystectomy (OC)
    Manthri, Sukesh
    Bastos, Bruno R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] A phase II trial of risk-adapted treatment for muscle invasive bladder cancer after neoadjuvant accelerated MVAC.
    Geynisman, Daniel M.
    Abbosh, Philip
    Zibelman, Matthew R.
    Feldman, Rebecca
    McConkey, David James
    Hahn, Noah M.
    Bivalacqua, Trinity
    Trabulsi, Edouard John
    Lallas, Costas D.
    Hoffman-Censits, Jean H.
    Viterbo, Rosalia
    Horwitz, Eric M.
    Churilla, Thomas M.
    Alpaugh, R. Katherine
    Greenberg, Richard E.
    Smaldone, Marc C.
    Uzzo, Robert
    Chen, David
    Kutikov, Alexander
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [49] Durvalumab (D) plus /- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial
    Thibault, C.
    Bennamoun, M.
    Flechon, A.
    Gravis, G.
    Pouessel, D.
    Combe, P-F.
    Borchiellini, D.
    Loriot, Y.
    Laguerre, B.
    Barthelemy, P.
    Goupil, M. Gross
    Helissey, C.
    Huillard, O.
    Cancel, M.
    Campedel, L.
    Audenet, F.
    Belhouari, H.
    Kotti, S.
    Tran, Y.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1202 - S1202
  • [50] Neoadjuvant nivolumab, gemcitabine and cisplatin in muscle-invasive bladder cancer: Study update
    Gupta, Shilpa
    Weight, Christopher J.
    Agarwal, Neeraj
    Gupta, Sumati
    Konety, Badrinath
    Gibb, Ewan
    Davicioni, Elai
    Thyagarajan, Bharat
    Sonpavde, Guru
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
12345